Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3114-3120

  Williams, Kathy ^a   Minkowski, Austin ^a   Amoabeng, Opokua ^a   Peloquin, Charles A ^b   Taylor, Dinesh ^a   Andries, Koen ^c   Wallis, Robert S ^d   Mdluli, Khisimuzi E ^e   Nuermberger, Eric L ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c TIBOTEC BVBA   (Belgium)

^d PFIZER INC   (United States)

^e Global Alliance for TB Drug Development   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CLOFAZIMINE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; SUTEZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLIDINONES; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861137329     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00384-12     Document Type: Article

References (47)

1. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. 2009. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13:79-83.
2. Ahmad Z, et al. 2011. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J. Antimicrob. Chemother. 66:1560-1566.
3. Alffenaar JW, et al. 2011. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob. Agents Chemother. 55:1287-1289.
4. Andries K, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. (Pubitemid 40116230)
5. Banerjee DK, Ellard GA, Gammon PT, Waters MF. 1974. Some observations on the pharmacology of clofazimine (B663). Am. J. Trop. Med. Hyg. 23:1110-1115.
6. Conde MB, et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
7. Davis SL, et al. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy- Dglucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
8. De Groote MA, et al. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:1237-1247.
9. De Groote MA, et al. 2012. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:731-738.
10. de Steenwinkel JE, et al. 2011. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size. Int. J. Tuberc. Lung Dis. 15:1478-1484.
11. Diacon AH, et al. 2009. The diarylquinoline TMC207 for multidrugresistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
12. Grimaldo ER, et al. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546-550. (Pubitemid 32587285)
13. Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47:833-836. (Pubitemid 36254203)
14. Harper J, et al. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595-602.
15. Hoff DR, et al. 2011. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6:e17550.
16. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180:553-557.
17. Ji B, Lounis N, Truffot-Pernot C, Grosset J. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 38:2521-2529. (Pubitemid 24332580)
18. Kim HJ, et al. 2012. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int. J. Tuberc. Lung Dis. 16:98-103.
19. Lounis N, et al. 2008. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J. Clin. Microbiol. 46:2212-2215.
20. Lounis N, et al. 2006. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547. (Pubitemid 44684863)
21. Lu P, et al. 2011. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels. Antimicrob. Agents Chemother. 55:5354-5357.
22. Lu Y, et al. 2011. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob. Agents Chemother. 55:5185-5193.
23. Matsumoto M, et al. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466.
24. Mdluli K. 2011. Combination therapy with novel TB drugs. Progr. Abstr. Fourth Int. Workshop Clin. Pharmacol. Tuberculosis Drugs, Chicago, IL, 16 September 2011. Virology Education B.V., Utrecht, The Netherlands. http://regist2.virology-education.com/2011/4TB-PK/docs/07-Mdluli.pdf.
25. Mphahlele M, et al. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459 -3464.
26. Nuermberger E, et al. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524. (Pubitemid 351522025)
27. Nuermberger EL, et al. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134. (Pubitemid 39488628)
28. Pierre-Audigier C, et al. 2012. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 16:221-223.
29. Reddy VM, O'Sullivan JF, Gangadharam PR. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623. (Pubitemid 29231686)
30. Rosenthal IM, et al. 2005. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462. (Pubitemid 43069821)
31. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989-993.
32. Rosenthal IM, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344.
33. Rouan MC, et al. 2012. Pharmacokinetics-pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56:1444-1451.
34. Rustomjee R, et al. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138. (Pubitemid 351212403)
35. Spigelman M, Woosley R, Gheuens J. 2010. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int. J. Tuberc. Lung Dis. 14:663-664.
36. Tasneen R, et al. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492.
37. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:3664-3668.
38. Tyagi S, et al. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293. (Pubitemid 40734456)
39. van Deun A, et al. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:684-692.
40. van Rensburg CE, Anderson R, O'Sullivan JF. 1997. Riminophenazine compounds: pharmacology and anti-neoplastic potential. Crit. Rev. Oncol. Hematol. 25:55-67. (Pubitemid 27138048)
41. Wallis RS, et al. 2011. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55:567-574.
42. Wallis RS, et al. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7:e30479.
43. Wallis RS, et al. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751.
44. Williams KN, et al. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376.
45. Williams KN, et al. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314 -1319.
46. Yano T, et al. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286:10276-10287.
47. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 184:732-737.